Cargando…
PB2276: MAHOGANY: A PHASE 3 TRIAL OF ZANUBRUTINIB PLUS ANTI-CD20 ANTIBODIES VS LENALIDOMIDE PLUS RITUXIMAB IN PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR OR MARGINAL ZONE LYMPHOMA
| Autores principales: | , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Lippincott Williams & Wilkins
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10429179/ http://dx.doi.org/10.1097/01.HS9.0000975836.58931.97 |
| _version_ | 1785090646075244544 |
|---|---|
| author | Silvestre, Antonio Salar Trotman, Judith Sarkozy, Clementine Song, Yuqin Sehn, Laurie H. Nastoupil, Loretta J. Zhang, Wanhua Fustier, Pierre Delarue, Richard Zinzani, Pier Luigi |
| author_facet | Silvestre, Antonio Salar Trotman, Judith Sarkozy, Clementine Song, Yuqin Sehn, Laurie H. Nastoupil, Loretta J. Zhang, Wanhua Fustier, Pierre Delarue, Richard Zinzani, Pier Luigi |
| author_sort | Silvestre, Antonio Salar |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10429179 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | Lippincott Williams & Wilkins |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-104291792023-08-17 PB2276: MAHOGANY: A PHASE 3 TRIAL OF ZANUBRUTINIB PLUS ANTI-CD20 ANTIBODIES VS LENALIDOMIDE PLUS RITUXIMAB IN PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR OR MARGINAL ZONE LYMPHOMA Silvestre, Antonio Salar Trotman, Judith Sarkozy, Clementine Song, Yuqin Sehn, Laurie H. Nastoupil, Loretta J. Zhang, Wanhua Fustier, Pierre Delarue, Richard Zinzani, Pier Luigi Hemasphere Publication Only Lippincott Williams & Wilkins 2023-08-08 /pmc/articles/PMC10429179/ http://dx.doi.org/10.1097/01.HS9.0000975836.58931.97 Text en Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially. |
| spellingShingle | Publication Only Silvestre, Antonio Salar Trotman, Judith Sarkozy, Clementine Song, Yuqin Sehn, Laurie H. Nastoupil, Loretta J. Zhang, Wanhua Fustier, Pierre Delarue, Richard Zinzani, Pier Luigi PB2276: MAHOGANY: A PHASE 3 TRIAL OF ZANUBRUTINIB PLUS ANTI-CD20 ANTIBODIES VS LENALIDOMIDE PLUS RITUXIMAB IN PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR OR MARGINAL ZONE LYMPHOMA |
| title | PB2276: MAHOGANY: A PHASE 3 TRIAL OF ZANUBRUTINIB PLUS ANTI-CD20 ANTIBODIES VS LENALIDOMIDE PLUS RITUXIMAB IN PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR OR MARGINAL ZONE LYMPHOMA |
| title_full | PB2276: MAHOGANY: A PHASE 3 TRIAL OF ZANUBRUTINIB PLUS ANTI-CD20 ANTIBODIES VS LENALIDOMIDE PLUS RITUXIMAB IN PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR OR MARGINAL ZONE LYMPHOMA |
| title_fullStr | PB2276: MAHOGANY: A PHASE 3 TRIAL OF ZANUBRUTINIB PLUS ANTI-CD20 ANTIBODIES VS LENALIDOMIDE PLUS RITUXIMAB IN PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR OR MARGINAL ZONE LYMPHOMA |
| title_full_unstemmed | PB2276: MAHOGANY: A PHASE 3 TRIAL OF ZANUBRUTINIB PLUS ANTI-CD20 ANTIBODIES VS LENALIDOMIDE PLUS RITUXIMAB IN PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR OR MARGINAL ZONE LYMPHOMA |
| title_short | PB2276: MAHOGANY: A PHASE 3 TRIAL OF ZANUBRUTINIB PLUS ANTI-CD20 ANTIBODIES VS LENALIDOMIDE PLUS RITUXIMAB IN PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR OR MARGINAL ZONE LYMPHOMA |
| title_sort | pb2276: mahogany: a phase 3 trial of zanubrutinib plus anti-cd20 antibodies vs lenalidomide plus rituximab in patients with relapsed or refractory follicular or marginal zone lymphoma |
| topic | Publication Only |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10429179/ http://dx.doi.org/10.1097/01.HS9.0000975836.58931.97 |
| work_keys_str_mv | AT silvestreantoniosalar pb2276mahoganyaphase3trialofzanubrutinibplusanticd20antibodiesvslenalidomideplusrituximabinpatientswithrelapsedorrefractoryfollicularormarginalzonelymphoma AT trotmanjudith pb2276mahoganyaphase3trialofzanubrutinibplusanticd20antibodiesvslenalidomideplusrituximabinpatientswithrelapsedorrefractoryfollicularormarginalzonelymphoma AT sarkozyclementine pb2276mahoganyaphase3trialofzanubrutinibplusanticd20antibodiesvslenalidomideplusrituximabinpatientswithrelapsedorrefractoryfollicularormarginalzonelymphoma AT songyuqin pb2276mahoganyaphase3trialofzanubrutinibplusanticd20antibodiesvslenalidomideplusrituximabinpatientswithrelapsedorrefractoryfollicularormarginalzonelymphoma AT sehnlaurieh pb2276mahoganyaphase3trialofzanubrutinibplusanticd20antibodiesvslenalidomideplusrituximabinpatientswithrelapsedorrefractoryfollicularormarginalzonelymphoma AT nastoupillorettaj pb2276mahoganyaphase3trialofzanubrutinibplusanticd20antibodiesvslenalidomideplusrituximabinpatientswithrelapsedorrefractoryfollicularormarginalzonelymphoma AT zhangwanhua pb2276mahoganyaphase3trialofzanubrutinibplusanticd20antibodiesvslenalidomideplusrituximabinpatientswithrelapsedorrefractoryfollicularormarginalzonelymphoma AT fustierpierre pb2276mahoganyaphase3trialofzanubrutinibplusanticd20antibodiesvslenalidomideplusrituximabinpatientswithrelapsedorrefractoryfollicularormarginalzonelymphoma AT delaruerichard pb2276mahoganyaphase3trialofzanubrutinibplusanticd20antibodiesvslenalidomideplusrituximabinpatientswithrelapsedorrefractoryfollicularormarginalzonelymphoma AT zinzanipierluigi pb2276mahoganyaphase3trialofzanubrutinibplusanticd20antibodiesvslenalidomideplusrituximabinpatientswithrelapsedorrefractoryfollicularormarginalzonelymphoma |